Alder BioPharmaceuticals: Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SEC

· Updated tender offer materials provide additional summary information regarding existing Lundbeck offer terms, including existing CVR terms, and additional information regarding existing Alder director and officer share ownership · Offer terms remain unchanged from commencement, with Lundbeck offering Alder stockholders upfront payment of USD 18.00 per share in cash along with one non-tradeable Contingent Value Right for USD 2.00 per share contingent on upon approval of eptinezumab by the European Medicines Agency Valby, Denmark and Bothell, Washington, USA, 11 October 2019 - H.